Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Anda

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

- PMLiVE

Depression drug failure adds to Allergan’s woes

Axe hangs over remaining monotherapy and suicidality trials

- PMLiVE

Teva will have to endure revenue ‘trough’ in 2019

Company looks to migrane treatment Ajovy for growth

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Generic Differentiation

Even in the cost-led market for generics, differentiated business models evolve

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

- PMLiVE

Teva wins FDA OK for crucial migraine drug

Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig

- PMLiVE

FDA rejects Allergan’s uterine fibroid drug over safety concerns

Its investigational drug has been linked to 'serious' liver damage issues in Europe

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links